GlassScriptPhysician profile
Christine J Pak
NPI 1598343360
$4,275.55
in general payments reported to CMS, 2019-2025
16 companies · $1,409 in 2025
The $1,409 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $624 · 2023: $1,274 · 2024: $968 · 2025: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,314 · Education: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,313.66 |
| Education | $337.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,383.23 | 2022-2025 | |
| Janssen Biotech, INC. | $763.15 | 2023-2025 | Tremfya |
| Genzyme Corporation | $693.08 | 2022-2025 | |
| Lilly USA, LLC | $438.82 | 2022-2025 | Taltz, Ebglyss |
| Sanofi-Aventis U.S. LLC | $149.98 | 2022-2025 | |
| Biofrontera INC. | $145.73 | 2022-2024 | Rhodoled Xl, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.67 | 2023 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $125.58 | 2022-2023 | Dupixent |
| Merz North America, INC. | $125.56 | 2023-2025 | |
| Stemline Therapeutics INC. | $122.11 | 2023 | Orserdu |
| Pfizer INC. | $57.62 | 2025 | |
| Merz Pharmaceuticals, LLC | $43.25 | 2024 | Xeomin |
| Helsinn Therapeutics (U.S.), INC. | $33.30 | 2022-2023 | Valchlor |
| Amgen INC. | $17.81 | 2025 | Otezla |
| Galderma Laboratories, L.P. | $17.70 | 2025 | Nemluvio |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $13.96 | 2025 | Bimzelx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Pak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.